Pediatric cardiac transplantation

Seminars in Pediatric Surgery

Volumn 15, Issue 3, 2006, Pages 188-198

  Alkhaldi, Abdulaziz ^a   Chin, Clifford ^a   Bernstein, Daniel ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

Cardiomyopathy; Congenital heart defects; Hypoplastic left heart syndrome; Myocarditis; Pediatric heart transplant; Ventricular dysfunction

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; ATORVASTATIN; AZATHIOPRINE; CALCINEURIN INHIBITOR; CALCIUM CHANNEL BLOCKING AGENT; CLONIDINE; CORTICOSTEROID; CYCLOSPORIN; DACLIZUMAB; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EVEROLIMUS; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 2 DERIVATIVE; LYMPHOCYTE ANTIBODY; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PRAVASTATIN; PREDNISONE; RAPAMYCIN; RITUXIMAB; STEROID; TACROLIMUS;

ARTICLE; ARTIFICIAL VENTILATION; BLOOD GROUP ABO SYSTEM; CARDIAC GRAFT REJECTION; CONGENITAL HEART MALFORMATION; DONOR; FIBROSING ALVEOLITIS; GLOMERULOSCLEROSIS; HEART ASSIST DEVICE; HEART TRANSPLANTATION; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; LYMPHOPROLIFERATIVE DISEASE; MICROANGIOPATHY; NEPHROTOXICITY; PATIENT SELECTION; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; QUALITY OF LIFE; SURGICAL TECHNIQUE; SURVIVAL; VASCULAR DISEASE;

AGE FACTORS; CARDIOMYOPATHIES; CHILD; HEART DEFECTS, CONGENITAL; HEART TRANSPLANTATION; HUMANS; INFANT; TREATMENT OUTCOME;

EID: 33745481297     PISSN: 10558586     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.sempedsurg.2006.03.011     Document Type: Article

References (113)

1. Boucek M.M., Edwards L.B., Keck B.M., et al. Registry of the International Society for Heart and Lung Transplantation. eighth official pediatric report-2005. J Heart Lung Transplant 24 (2005) 968-982
2. West L.J., Pollock-Barziv S.M., Dipchand A.I., et al. ABO-incompatible heart transplantation in infants. N Engl J Med 344 (2001) 793-800
3. Fullerton D.A., Gundry S.R., onso de B.J., et al. The effects of donor-recipient size disparity in infant and pediatric heart transplantation. J Thorac Cardiovasc Surg 104 (1992) 1314-1319
4. Razzouk A.J., Johnston J.K., Larsen R.L., et al. Effect of oversizing cardiac allografts on survival in pediatric patients with congenital heart disease. J Heart Lung Transplant 24 (2005) 195-199
5. Scheule A.M., Zimmerman G.J., Johnston J.K., et al. Duration of graft cold ischemia does not affect outcomes in pediatric heart transplant recipients. Circulation 106 12 (2002) I163-I167 2002 (suppl 1)
6. Razzouk A.J., Chinnock R.E., Gundry S.R., et al. Transplantation as a primary treatment for hypoplastic left heart syndrome. intermediate-term results. Ann Thorac Surg 62 (1996) 1-7
7. Bailey L.L., Gundry S.R., Razzouk A.J., et al., The Loma Linda University Pediatric Heart Transplant Group. Bless the babies. one hundred fifteen late survivors of heart transplantation during the first year of life. J Thorac Cardiovasc Surg 105 (1993) 805-814
8. Kawauchi M., Gundry S.R., de Begona J.A., et al. Prolonged preservation of human pediatric hearts for transplantation. correlation of ischemic time and subsequent function. J Heart Lung Transplant 12 (1993) 55-58
9. Mitchell M.B., Campbell D.N., Clarke D.R., et al. Infant heart transplantation. improved intermediate results. J Thorac Cardiovasc Surg 116 (1998) 242-252
10. Canter C., Naftel D., Caldwell R., et al. Survival and risk factors for death after cardiac transplantation in infants. A multi-institutional study. The Pediatric Heart Transplant Study. Circulation 96 (1997) 227-231
11. Fernandez J., Aranda J., Mabbot S., et al. Overseas procurement of donor hearts. ischemic time effect on postoperative outcomes. Transplant Proc 33 (2001) 3803-3804
12. Chin C., Miller J., Robbins R., et al. The use of advanced-age donor hearts adversely affects survival in pediatric heart transplantation. Pediatr Transplant 3 (1999) 309-314
13. Zaroff J.G., Rosengard B.R., Armstrong W.F., et al. Consensus conference report: maximizing use of organs recovered from the cadaver donor: cardiac recommendations. Circulation 106 (2002) 836-841
14. Shumway N.E., Lower R.R., and Stofer R.C. Transplantation of the heart. Adv Surg 2 (1966) 265-284
15. Sievers H.H., Weyand M., Kraatz E.G., et al. An alternative technique for orthotopic cardiac transplantation, with preservation of the normal anatomy of the right atrium. Thorac Cardiovasc Surg 39 (1991) 70-72
16. Sarsam M.A., Campbell C.S., Yonan N.A., et al. An alternative surgical technique in orthotopic cardiac transplantation. J Card Surg 8 (1993) 344-349
17. El Gamel A., Deiraniya A.K., Rahman A.N., et al. Orthotopic heart transplantation hemodynamics. does atrial preservation improve cardiac output after transplantation?. J Heart Lung Transplant 15 (1996) 564-571
18. El Gamel A., Yonan N.A., Grant S., et al. Orthotopic cardiac transplantation. a comparison of standard and bicaval Wythenshawe techniques. J Thorac Cardiovasc Surg 109 (1995) 721-729
19. Sievers H.H., Leyh R., Jahnke A., et al. Bicaval versus atrial anastomoses in cardiac transplantation. Right atrial dimension and tricuspid valve function at rest and during exercise up to thirty-six months after transplantation. J Thorac Cardiovasc Surg 108 (1994) 780-784
20. Rothman S.A., Jeevanandam V., Combs W.G., et al. Eliminating bradyarrhythmias after orthotopic heart transplantation. Circulation 94 9, suppl (1996) II278-II282
21. Bleasdale R.A., Banner N.R., Anyanwu A.C., et al. Determinants of outcome after heterotopic heart transplantation. J Heart Lung Transplant 21 (2002) 867-873
22. Ridley P.D., Khaghani A., Musumeci F., et al. Heterotopic heart transplantation and recipient heart operation in ischemic heart disease. Ann Thorac Surg 54 (1992) 333-337
23. Desruennes M., Muneretto C., Gandjbakhch I., et al. Heterotopic heart transplantation. current status in 1988. J Heart Transplant 8 (1989) 479-485
24. Kawaguchi A., Gandjbakhch I., Pavie A., et al. Factors affecting survival after heterotopic heart transplantation. J Thorac Cardiovasc Surg 98 5 (1989) 928-934
25. Nakatani T., Frazier O.H., Lammermeier D.E., et al. Heterotopic heart transplantation. a reliable option for a select group of high-risk patients. J Heart Transplant 8 (1989) 40-47
26. Michler R.E., and Sandhu A.A. Novel approach for orthotopic heart transplantation in visceroatrial situs inversus. Ann Thorac Surg 60 (1995) 194-197
27. Vricella L.A., Razzouk A.J., Gundry S.R., et al. Heart transplantation in infants and children with situs inversus. J Thorac Cardiovasc Surg 116 (1998) 82-89
28. Hershberger R.E., Starling R.C., Eisen H.J., et al. Daclizumab to prevent rejection after cardiac transplantation. N Engl J Med 352 (2005) 2705-2713
29. Eisen H.J., Tuzcu E.M., Dorent R., et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 349 (2003) 847-858
30. Keogh A., Richardson M., Ruygrok P., et al. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years. a randomized clinical trial. Circulation 110 (2004) 2694-2700
31. Sindhi R. Sirolimus in pediatric transplant recipients. Transplant Proc 35 3, suppl (2003) 113S-114S
32. Straatman L.P., and Coles J.G. Pediatric utilization of rapamycin for severe cardiac allograft rejection. Transplant 70 (2000) 541-543
33. Haddad H., MacNeil D.M., Howlett J., et al. Sirolimus, a new potent immunosuppressant agent for refractory cardiac transplantation rejection. two case reports. Can J Cardiol 16 (2000) 221-224
34. Levy G., Burra P., Cavallari A., et al. Improved clinical outcomes for liver transplant recipients using cyclosporine monitoring based on 2-hr post-dose levels (C2). Transplant 73 (2002) 953-959
35. Cantarovich M., Elstein E., de Varennes B., et al. Clinical benefit of neoral dose monitoring with cyclosporine 2-hr post-dose levels compared with trough levels in stable heart transplant patients. Transplant 68 (1999) 1839-1842
36. Cantarovich M., Quantz M., Elstein E., et al. Neoral dose monitoring with cyclosporine 2-hour postdose levels in heart transplant patients receiving anti-thymocyte globulin induction. Transplant Proc 32 (2000) 446-448
37. Morton J.M., Aboyoun C.L., Malouf M.A., et al. Enhanced clinical utility of de novo cyclosporine C2 monitoring after lung transplantation. J Heart Lung Transplant 23 (2004) 1035-1039
38. Bhargava H., Donner R.M., Sanchez G., et al. Endomyocardial biopsy after heart transplantation in children. J Heart Transplant 6 (1987) 298-302
39. Chin C., Akhtar M.J., Rosenthal D.N., et al. Safety and utility of the routine surveillance biopsy in pediatric patients 2 years after heart transplantation. J Pediatr 136 (2000) 238-242
40. Chin C., Naftel D.C., Singh T.P., et al. Risk factors for recurrent rejection in pediatric heart transplantation. a multicenter experience. J Heart Lung Transplant 23 (2004) 178-185
41. Caves P.K., Stinson E.B., Billingham M.E., et al. Diagnosis of human cardiac allograft rejection by serial cardiac biopsy. J Thorac Cardiovasc Surg 66 (1973) 461-466
42. Caves P.K., Stinson E.B., Billingham M.E., et al. Serial transvenous biopsy of the transplanted human heart. Improved management of acute rejection episodes. Lancet 1 (1974) 821-826
43. Billingham M.E. Some recent advances in cardiac pathology. Hum Pathol 10 (1979) 367-386
44. Mehra M.R., and Kobashigawa J.A. Advances in heart and lung transplantation 2004. Report from the 24th International Society for Heart and Lung Transplantation Annual Meeting, San Francisco, April 21-24, 2004. J Heart Lung Transplant 23 (2004) 925-930
45. Deng M.C., Mehra M.R., and Eisen H.J. Cardiac allograft monitoring using a novel clinical algorithm based on peripheral leukocyte gene expression profiling. Circulation 108 suppl (2003) 1801
46. Mehra M.R., Kobashigawa J., Hunt S., et al. Molecular testing and prediction of clinical outcome in heart transplantation. a prospective multicenter trial. J Heart Lung Transplant 23 suppl (2004) S106
47. Ross M., Kouretas P., Gamberg P., et al. 10 and 20-Year survivors of pediatric orthotopic heart transplantation. J Heart Lung Transplant 25 (2006) 261-270
48. Chrisant M.R., Naftel D.C., Drummond-Webb J., et al. Fate of infants with hypoplastic left heart syndrome listed for cardiac transplantation. a multicenter study. J Heart Lung Transplant 24 (2005) 576-582
49. Bernstein D., Naftel D., Chin C., Addonizio L., Gamberg P., Hus D., et al. Outcome of listing for cardiac transplantation for failed Fontan. A follow-up multi-institutional study. J Heart Lung Transplant 23 (2004) S162
50. Schowengerdt K.O., Naftel D.C., Seib P.M., et al., The Pediatric Heart Transplant Study Group. Infection after pediatric heart transplantation. results of a multiinstitutional study. J Heart Lung Transplant 16 (1997) 1207-1216
51. Pahl E., Fricker F.J., Trento A., et al. Late follow-up of children after heart transplantation. Transplant Proc 20 1, suppl 1 (1988) 743-746
52. Schroeder J.S., Gao S.Z., Alderman E.L., et al. A preliminary study of diltiazem in the prevention of coronary artery disease in heart-transplant recipients. N Engl J Med 328 (1993) 164-170
53. Schroeder J.S., and Gao S.Z. Calcium blockers and atherosclerosis. lessons from the Stanford Transplant Coronary Artery Disease/Diltiazem Trial. Can J Cardiol 11 (1995) 710-715
54. English J., Evan A., Houghton D.C., et al. Cyclosporine-induced acute renal dysfunction in the rat. Evidence of arteriolar vasoconstriction with preservation of tubular function. Transplantation 44 (1987) 135-141
55. Mihatsch M.J., Thiel G., and Ryffel B. Histopathology of cyclosporine nephrotoxicity. Transplantat Proc 20 3, suppl 3 (1988) 759-771
56. Mihatsch M.J., Thiel G., and Ryffel B. Morphologic diagnosis of cyclosporine nephrotoxicity. Semin Diagn Pathol 5 (1988) 104-121
57. Chinnock R., Baum M., Chinnock R., et al. Somatic growth in infant heart transplant recipients. Pediatr Transplant 2 (1998) 30-34
58. Hirsch R., Huddleston C.B., Mendeloff E.N., et al. Infant and donor organ growth after heart transplantation in neonates with hypoplastic left heart syndrome. J Heart Lung Transplant 15 (1996) 1093-1100
59. Bernstein D., Kolla S., Miner M., et al. Cardiac growth after pediatric heart transplantation. Circulation 85 (1992) 1433-1439
60. Zales V.R., Wright K.L., Pahl E., et al. Normal left ventricular muscle mass and mass/volume ratio after pediatric cardiac transplantation. Circulation 90 5 (1994) II61-II65
61. Glendenning P., Kent G.N., Adler B.D., et al. High prevalence of osteoporosis in cardiac transplant recipients and discordance between biochemical turnover markers and bone histomorphometry. Clin Endocrinol 50 (1999) 347-355
62. Shane E., Rivas M., McMahon D.J., et al. Bone loss and turnover after cardiac transplantation. J Clin Endocrinol Metab 82 (1997) 1497-1506
63. Sambrook P.N., Kelly P.J., Keogh A.M., et al. Bone loss after heart transplantation. a prospective study. J Heart Lung Transplant 13 1 (1994) 116-120
64. Cohen A., Addonizio L.J., Lamour J.M., et al. Osteoporosis in adult survivors of adolescent cardiac transplantation may be related to hyperparathyroidism, mild renal insufficiency, and increased bone turnover. J Heart Lung Transplant 24 (2005) 696-702
65. Ho M., Jaffe R., Miller G., et al. The frequency of Epstein-Barr virus infection and associated lymphoproliferative syndrome after transplantation and its manifestations in children. Transplant 45 (1988) 719-727
66. Chadburn A., Cesarman E., and Knowles D.M. Molecular pathology of posttransplantation lymphoproliferative disorders. Semin Diagn Pathol 14 (1997) 15-26
67. Zangwill S.D., Hsu D.T., Kichuk M.R., et al. Incidence and outcome of primary Epstein-Barr virus infection and lymphoproliferative disease in pediatric heart transplant recipients. J Heart Lung Transplant 17 (1998) 1161-1166
68. Bernstein D., Baum D., Berry G., et al. Neoplastic disorders after pediatric heart transplantation. Circulation 88 5 (1993) II230-II237
69. Costanzo M.R., Naftel D.C., Pritzker M.R., et al. Heart transplant coronary artery disease detected by coronary angiography. a multiinstitutional study of preoperative donor and recipient risk factors. Cardiac Transplant Research Database. J Heart Lung Transplant 17 (1998) 744-753
70. Taylor D.O., Edwards L.B., Boucek M.M., Trulock E.P., Keck B.M., and Hertz M.I. The Registry of the International Society for Heart and Lung Transplantation. twenty-first official adult heart transplant report-2004. J Heart Lung Transplant 23 (2004) 796-803
71. Valantine H., Rickenbacker P., Kemna M., et al. Metabolic abnormalities characteristic of dysmetabolic syndrome predict the development of transplant coronary artery disease. a prospective study. Circulation 103 (2001) 2144-2152
72. Costanzo-Nordin M.R. Cardiac allograft vasculopathy. relationship with acute cellular rejection and histocompatibility. J Heart Lung Transplant 11 3 (1992) S90-S103
73. Grattan M.T., Moreno-Cabral C.E., Starnes V.A., et al. Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. JAMA 261 (1989) 3561-3566
74. Kobashigawa J.A., Miller L., Yeung A., et al., Sandoz/CVIS Investigators. Does acute rejection correlate with the development of transplant coronary artery disease? A multicenter study using intravascular ultrasound. J Heart Lung Transplant 14 6 (1995) S221-S226
75. Valantine H. Cardiac allograft vasculopathy after heart transplantation. risk factors and management. J Heart Lung Transplant 23 5, suppl (2004) S187-S193
76. Tham E.B.C., Yeung A.C., Cheng C.W.B., et al. Experience of percutaneous coronary intervention in the management of pediatric cardiac allograft vasculopathy. J Heart Lung Transplant 24 (2005) 769-773
77. Radovancevic B., McGiffin D.C., Kobashigawa J.A., et al. Retransplantation in 7,290 primary transplant patients. a 10-year multi-institutional study. J Heart Lung Transplant 22 (2003) 862-868
78. Kanter K.R., Vincent R.N., Berg A.M., et al. Cardiac retransplantation in children. Ann Thorac Surg 78 (2004) 644-649
79. Dearani J.A., Razzouk A.J., Gundry S.R., et al. Pediatric cardiac retransplantation. intermediate-term results. Ann Thorac Surg 71 (2001) 66-70
80. Razzouk A.J., Chinnock R.E., Dearani J.A., et al. Cardiac retransplantation for graft vasculopathy in children. should we continue to do it?. Arch Surg 133 (1998) 881-885
81. Chin C., Rosenthal D., and Bernstein D. Lipoprotein abnormalities are highly prevalent in pediatric heart transplant recipients. Pediatr Transplant 4 (2000) 193-199
82. Seipelt I.M., Crawford S.E., Rodgers S., et al. Hypercholesterolemia is common after pediatric heart transplantation. initial experience with pravastatin. J Heart Lung Transplant 23 (2004) 317-322
83. Chin C., Gamberg P., Miller J., et al. Efficacy and safety of atorvastatin after pediatric heart transplantation. J Heart Lung Transplant 21 (2002) 1213-1217
84. Cutts J.L., and Bankhurst A.D. Reversal of lovastatin-mediated inhibition of natural killer cell cytotoxicity by interleukin 2. J Cell Physiol 145 (1990) 244-252
85. Cutts J.L., Scallen T.J., Watson J., et al. Role of mevalonic acid in the regulation of natural killer cell cytotoxicity. J Cell Physiol 139 (1989) 550-557
86. Kobashigawa J.A., Katznelson S., Laks H., et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 333 (1995) 621-627
87. Meiser B.M., Billingham M.E., and Morris R.E. Effects of cyclosporin, FK506, and rapamycin on graft-vessel disease. Lancet 338 (1991) 1297-1298
88. Mancini D., Pinney S., Burkhoff D., et al. Use of rapamycin slows progression of cardiac transplantation vasculopathy. Circulation 108 (2003) 48-53
89. Ruygrok P.N., Webber B., Faddy S., et al. Angiographic regression of cardiac allograft vasculopathy after introducing sirolimus immunosuppression. J Heart Lung Transplant 22 (2003) 1276-1279
90. Wray J., and Radley-Smith R. Depression in pediatric patients before and 1 year after heart or heart-lung transplantation. J Heart Lung Transplant 23 (2004) 1103-1110
91. Wray J., Long T., Radley-Smith R., et al. Returning to school after heart or heart-lung transplantation. how well do children adjust?. Transplantation 72 (2001) 100-106
92. Fiser W.P., Yetman A.T., Gunselman R.J., et al. Pediatric arteriovenous extracorporeal membrane oxygenation (ECMO) as a bridge to cardiac transplantation. J Heart Lung Transplant 22 (2003) 770-777
93. Helman D.N., Addonizio L.J., Morales D.L., et al. Implantable left ventricular assist devices can successfully bridge adolescent patients to transplant. J Heart Lung Transplant 19 (2000) 121-126
94. Ashton Jr. R.C., Oz M.C., Michler R.E., et al. Left ventricular assist device options in pediatric patients. ASAIO J 41 (1995) M277-M280
95. McBride L.R., Naunheim K.S., Fiore A.C., et al. Clinical experience with 111 Thoratec ventricular assist devices. Ann Thorac Surg 67 (1999) 1233-1238
96. Korfer R., El-Banayosy A., Arusoglu L., et al. Single-center experience with the Thoratec ventricular assist device. J Thorac Cardiovasc Surg 119 (2000) 596-600
97. Reinhartz O., Keith F.M., El-Banayosy A., et al. Multicenter experience with the Thoratec ventricular assist device in children and adolescents. J Heart Lung Transplant 20 (2001) 439-448
98. 2 of body surface area. ASAIO J 49 (2003) 727-730
99. Hetzer R., Loebe M., Potapov E.V., et al. Circulatory support with pneumatic paracorporeal ventricular assist device in infants and children. Ann Thorac Surg 66 (1998) 1498-1506
100. Esmore D.S., Spratt P.M., Keogh A.M., et al. Cyclosporine and azathioprine immunosuppression without maintenance steroids. a prospective randomized trial. J Heart Transplant 8 (1989) 194-199
101. Lee K.F., Pierce J.D., Hess M.L., et al. Cardiac transplantation with corticosteroid-free immunosuppression. long-term results. Ann Thorac Surg 52 (1991) 211-217
102. Renlund D.G., O'Connell J.B., Gilbert E.M., et al. Feasibility of discontinuation of corticosteroid maintenance therapy in heart transplantation. J Heart Lung Transplant 6 (1987) 71-78
103. Canter C.E., Moorhead S., Saffitz J.E., et al. Steroid withdrawal in the pediatric heart transplant recipient initially treated with triple immunosuppression. J Heart Lung Transplant 13 (1994) 74-79
104. Kobashigawa J.A., Stevenson L.W., Brownfield E.D., et al. Initial success of steroid weaning late after heart transplantation. J Heart Lung Transplant 11 (1992) 428-430
105. Miller L.W., Wolford T., McBride L.R., et al. Successful withdrawal of corticosteroids in heart transplantation. J Heart Lung Transplant 11 (1992) 431-434
106. Oaks T.E., Wannenberg T., Close S.A., et al. Steroid-free maintenance immunosuppression after heart transplantation. Ann Thorac Surg 72 (2001) 102-106
107. Felkel T.O., Smith A.L., Reichenspurner H.C., et al. Survival and incidence of acute rejection in heart transplant recipients undergoing successful withdrawal from steroid therapy. J Heart Lung Transplant 21 (2002) 530-539
108. Mehra M.R., Ventura H.O., Smart F.W., et al. An intravascular ultrasound study of the influence of angiotensin-converting enzyme inhibitors and calcium entry blockers on the development of cardiac allograft vasculopathy. Am J Cardiol 75 (1995) 853-854
109. Taylor D.O., Ensley R.D., Olsen S.L., et al. Mycophenolate mofetil (RS-61443). preclinical, clinical, and three-year experience in heart transplantation. J Heart Lung Transplant 13 (1994) 571-582
110. Robbins R.C., Barlow C.W., Oyer P.E., et al. Thirty years of cardiac transplantation at Stanford university. J Thorac Cardiovasc Surg 117 (1999) 939-951
111. Redonnet M., Tron C., Koning R., et al. Coronary angioplasty and stenting in cardiac allograft vasculopathy following heart transplantation. Transplant Proc 32 (2000) 463-465
112. Halle III A.A., Wilson R.F., Massin E.K., et al. Coronary angioplasty in cardiac transplant patients. Results of a multicenter study. Circulation 86 (1992) 458-462
113. Halle III A.A., DiSciascio G., Massin E.K., et al. Coronary angioplasty, atherectomy and bypass surgery in cardiac transplant recipients. J Am Coll Cardiol 26 (1995) 120-128